LONGMONT, Colo., May 7, 2024
/PRNewswire/ -- KromaTiD, a company focused on the research,
development, and commercialization of single-cell genomics tools
and services for the Cell and Gene Therapy (C>) Market, is
launching GLP Genomic Integrity Karyotyping services at the 2024
American Society for Gene and Cell Therapy (ASGCT) Meeting in
Baltimore, Booth 2217, May
7–11.
"This expansion of our best-in-class assays for the C>
community ensures that we can effectively partner with drug product
producers throughout their pipeline journey, from the earliest
development stages to IND filing to clinical batch release, where
operating in a GLP environment is needed," says newly appointed
KromaTiD CEO Jim Chomas. "We are
committed to constantly improving and innovating our offerings to
keep pace with the evolving requirements for cell and gene therapy
product approvals. Whatever we can do to help get these
therapeutics to the people who need them, we will do."
KromaTiD's Genomic Integrity (GI) Karyotyping service was
developed in collaboration with KromaTiD's many leading C>
customers specifically to address the challenges of producing novel
cell and gene therapy products such as CAR-T and CAR-NK.
GI Karyotyping from KromaTiD offers a comprehensive analysis
of all classes of genomic structural variants with the depth of
analysis required to detect the low frequency events that may occur
in cell and gene therapy drug products.
"Our approach to genomic integrity analysis for our cell and
gene therapy customers is to write a measurement specification
customized to the requirements of their cell product," says
KromaTiD Chief Technology Officer Christopher Tompkins. "Using this approach
allows us to detect the specific structural variants, for instance
edit-associated translocations, at the frequency that matters for a
specific product. This is often below one percent, given the high
quality of the genome edits performed by our customers."
KromaTiD's Genomic Integrity analysis pipeline begins with
unbiased G-band karyotyping that is based on measurements of both
the donor and edited cells, providing valuable information on
genomic structural variants related to both the editing and cell
product expansion process in the same test. KromaTiD then
provides this data as a variance from the donor cells in its
Genomic Integrity Pair-Wise Comparison Report. For customers
needing resolution beyond the ~10 mb provided by G-banding,
KromaTiD offers other Genomic Integrity assays based on their
proprietary directional Genomic Hybridization (dGH™) platform
product, providing at least two orders of magnitude improved
resolution for structural variant detection.
KromaTiD will be featuring their full suite of single cell
genomic assays at this year's ASGCT meeting, including:
- Genomic Integrity Karyotyping: Confirmatory mapping of
low prevalence, edit-associated chromosomal structural variation,
identification of sub-clonal cell populations and monitoring of
cell and gene therapy batch stability.
- dGH SCREEN™: Single cell, unbiased and ultra-high-resolution
mapping of structural variants as small as 5 kb.
- dGH DISCVR™: A highly resolved, unbiased approach for tracking
genomic segmental rearrangements and complex structural
variation.
- dGH in-Site™: Direct, single-cell visualization of the
structure of on- and off-target DNA edit sites and mapping of
transgene insertions anywhere in the genome.
About KromaTiD, Inc.
KromaTiD supports research teams in academia, large
pharmaceutical, and therapeutic companies with expert scientific
support and unparalleled genomics tools and services. We are your
partner for biomarker discovery, genomic integrity analysis of
engineered cell products and structural genomic assessment.
KromaTiD.com
For KromaTiD Information Contact:
Stephanie Elena at
818-723-7962
377280@email4pr.com
View original
content:https://www.prnewswire.com/news-releases/kromatid-expands-their-gene-therapy-analytic-assay-suite-with-the-addition-of-glp-genomic-integrity-karyotyping-services-302137647.html
SOURCE KromaTiD, Inc.